The adipokine chemerin retinoic acid receptor responder protein 2 (RARRES2) has been associated with insulin resistance, type II diabetes mellitus (T2DM), obesity, and metabolic syndrome (MetS). The impact of RARRES2 rs17173608 gene polymorphism on MetS and chemerin levels is not completely elucidated. This study included 100 patients with MetS and 68 healthy subjects (non-MetS group). The RARRES2 rs17173608 gene variant was analyzed by tetra amplification refractory mutation system polymerase chain reaction (T-ARMS-PCR). Circulating chemerin levels were determined by ELISA. Serum urea, creatinine, fasting blood glucose, glycated hemoglobin, and traditional lipid profile were measured by colorimetric methods. The estimated glomerular filtration rate (eGFR) and non-traditional lipid parameters were calculated. Serum chemerin levels were significantly higher in MetS than in non-MetS subjects, type II diabetics (T2DM) than non-diabetics, and overweight compared to lean subjects, but it did not differ significantly between patients with and without hypertension. Strikingly, newly diagnosed diabetic patients had significantly higher serum chermerin levels. Correlation and multiple linear regression analysis showed that serum chemerin levels and non-traditional lipid parameters were correlated significantly with the clinical criteria of MetS. Genotyping and allelic frequency distribution of RARRES2 rs17173608 gene polymorphism showed its significant association with MetS. The TT genotype of RARRES2 rs17173608 SNP was more distributed in T2DM in comparison with non-diabetics, and it was associated significantly with higher serum chemerin and higher glycated hemoglobin levels. RARRES2 rs17173608 GG genotype and G allele frequency were less distributed in T2DM patients than in non-diabetic patients. The RARRES2 rs17173608 SNP might have an impact on chemerin levels and lipid parameters. The GG genotype and G allele may have a protective role towards the risk of T2DM but not for MetS. Serum chemerin and non-traditional lipid profile are significantly associated with MetS.

中文翻译：

---

代谢综合征患者RARRES2 rs17173608基因多态性、血清chemerin与非传统血脂水平的关系

脂肪因子凯莫瑞视黄酸受体反应蛋白 2 (RARRES2) 与胰岛素抵抗、II 型糖尿病 (T2DM)、肥胖和代谢综合征 (MetS) 相关。RARRES2 rs17173608 基因多态性对 MetS 和 chemerin 水平的影响尚未完全阐明。该研究包括 100 名 MetS 患者和 68 名健康受试者（非 MetS 组）。RARRES2 rs17173608 基因变体通过四扩增难治突变系统聚合酶链反应 (T-ARMS-PCR) 进行分析。通过ELISA确定循环chemerin水平。通过比色法测量血清尿素、肌酐、空腹血糖、糖化血红蛋白和传统血脂谱。计算估计的肾小球滤过率 (eGFR) 和非传统脂质参数。MetS 患者的血清 chemerin 水平显着高于非 MetS 受试者，II 型糖尿病患者 (T2DM) 高于非糖尿病患者，超重与瘦受试者相比，但在患有和不患有高血压的患者之间没有显着差异。引人注目的是，新诊断的糖尿病患者的血清chermerin水平显着升高。相关性和多元线性回归分析显示血清chemerin水平和非传统脂质参数与MetS的临床标准显着相关。RARRES2 rs17173608 基因多态性的基因分型和等位基因频率分布显示其与 MetS 显着相关。与非糖尿病患者相比，RARRES2 rs17173608 SNP 的 TT 基因型在 T2DM 中分布更多，它与较高的血清凯莫瑞和较高的糖化血红蛋白水平显着相关。RARRES2 rs17173608 GG 基因型和 G 等位基因频率在 T2DM 患者中的分布低于非糖尿病患者。RARRES2 rs17173608 SNP 可能对凯莫瑞水平和脂质参数产生影响。GG 基因型和 G 等位基因可能对 T2DM 的风险有保护作用，但对 MetS 没有保护作用。血清凯莫瑞和非传统脂质谱与 MetS 显着相关。